This investment supports the ongoing development of a new Artificial Intelligence / Machine Learning derived brain-activity based biomarker to predict future onset of Alzheimer's. The company is also evaluating whether its trauma related, FDA-cleared brain bleed biomarker might be effective in detecting ARIAs, a serious side effect of the newly FDA approved Alzheimer's drugs, so that patients might avoid the expensive and time-consuming multiple MRI scans that are currently recommended.BrainScope is a medical neurotechnology company that is improving brain health by providing objective, diagnostic insights that enable better patient care.

这项投资支持正在进行的新的人工智能/机器学习衍生的基于大脑活动的生物标志物的开发，以预测未来阿尔茨海默病的发病。该公司还在评估其创伤相关的，FDA批准的脑出血生物标志物是否可能有效检测ARIAs，这是新FDA批准的阿尔茨海默病药物的严重副作用，因此患者可以避免昂贵且耗时的多次MRI扫描。目前推荐。BrainScope是一家医疗神经技术公司，通过提供客观的诊断见解来改善大脑健康，从而实现更好的患者护理。

BrainScope is leading the way in the rapid and objective assessment of brain injury and disease, starting with mild traumatic brain injury (mTBI). The commercially available, FDA-cleared, non-invasive handheld device with integrated brain activity biomarkers helps clinicians quickly and confidently rule out the need for a head CT scan in patients with suspected mTBI while at the same time objectively assessing concussion in 15 minutes or less - demonstrated to save time, reduce radiation, improve patient throughput, and empower clinicians to provide patients the answers they are seeking..

从轻度创伤性脑损伤（mTBI）开始，BrainScope正在快速客观地评估脑损伤和疾病。具有集成脑活动生物标志物的市售，FDA批准的非侵入性手持设备可帮助临床医生快速，自信地排除疑似mTBI患者进行头部CT扫描的必要性，同时在15分钟或更短时间内客观评估脑震荡-证明可以节省时间，减少辐射，提高患者吞吐量，并授权临床医生为患者提供他们正在寻求的答案。。